Next Generation Sequencing Market Report, Size, Share, Opportunities, And Trends By Product and Services (Sequencing Systems, Consumables, Software, Sequencing Services and Analysis), By Technology (Sequencing by Synthesis, ION Torrent Sequencing, Nanopore Sequencing, Others), By Application (Agriculture and Animal Research, Biomarker Discovery, Drug Discovery, Diagnostics, Precision Medicine), And By Geography - Forecasts From 2025 To 2030

Report CodeKSI061610956
PublishedJul, 2025

Description

Next Generation Sequencing Market Size:

The next generation sequencing market is expected to grow from USD 16.696 billion in 2025 to USD 36.778 billion in 2030, at a CAGR of 17.11%.

Next Generation Sequencing Market Highlights:

  • Powering genome mapping: NGS is decoding full DNA sequences.
  • Driving oncology research: Tools are targeting cancer mutations.
  • Enhancing drug discovery: Platforms are identifying new targets.
  • Supporting infectious diagnostics: Systems are detecting pathogens fast.
  • Advancing exome analysis: Labs are focusing on coding regions.
  • Boosting academic studies: Institutes are expanding genomics.
  • Expanding biotech adoption: Companies are integrating NGS.

To learn more about this report, request a free sample copy

Next-generation sequencing (NGS) is a parallel sequencing technology that provides scalability, speed, and ultra-high throughput. The technology is then used to find the order of nucleotides in entire or complete genomes or various targeted areas and regions of RNA or DNA. NGS has modernized and advanced the biological sciences, enabling labs to perform a wide variety of applications and study biological systems at various levels.

Today's difficult and advanced genomics questions demand information that exceeds the capacity of traditional and commonly used DNA sequencing technologies. NGS has filled that gap and has become an everyday tool to address these questions. It allows labs to rapidly sequence whole genomes, deeply sequence target regions, utilize RNA sequencing (RNA-Seq) to discover novel RNA variants and splice sites, or quantify mRNAs for gene expression analysis, and has many other advantages over the old traditional methods.

The worldwide demand for next-generation sequencing (NGS) services and products is highly driven by a surge in the application of NGS, an increase in genome mapping programs, and a surge in collaborations, technological advancement in NGS technology, and various partnerships that result in significant investments in R&D in NGS technology.

The continuous technological advancements in the industry have led to the introduction of efficient, portable, and easy-to-use NGS platforms capable of providing rapid and accurate results, which have led to the overall growth in the industry. Such developments in the industry provide many new entrants in the industry and also give a competitive edge to the prominent companies in the industry, an edge over each other, which leads to more research and development programs in the industry. It is also driven by an increase in genome mapping programs; a rise in applications of next-generation sequencing; an increase in healthcare expenditure; and technological advancements in sequencing platforms. 

Next Generation Sequencing Market Growth Factors:

  • Support from the government and private sectors

A lot of developing countries have invested in their research and development sectors and in sequencing programs to get a deep knowledge of genetics and diseases. Many such government organizations have taken an active part in the sequencing program to find better ways for the treatment of cancer and other diseases. Due to this large support, several new entrants have entered the market as many sequencing projects have been introduced, which leads to the overall growth of this industry and gives growth opportunities to key players in the industry. Such type of growth has provided the wide-scale use of consumables required and the adoption of NSG instruments.

Next Generation Sequencing Market Restraints:

  • Lack of skill, power, and expenditure on Research and Development Programs

The expenditure on research and development in growing economies is mainly dependent on funding provided by external sources. Although governments and private bodies try to provide funds for the research programs, many research firms and academic institutes are facing budget problems and are not able to afford advanced and premium-priced equipment and technologies, which further leads to an effect on the growth of these industries and their expansion in developing nations. Also, the lack of skilled professionals in this industry is less in number which further hinders the growth of this industry. Due to this, the interpretation of complex data takes time, and researchers face difficulties, leading to slow growth in the industry.

Next Generation Sequencing Market Scope:

Report MetricDetails
Next Generation Sequencing Market Size in 2025USD 16.696 billion
Next Generation Sequencing Market Size in 2030USD 36.778 billion
Growth Rate17.11%
Study Period2020 to 2030
Historical Data2020 to 2023
Base Year2024
Forecast Period2025 – 2030
Forecast Unit (Value)Billion
SegmentationOfferings, Type, Method, Application
Geographical SegmentationNorth America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in Next Generation Sequencing Market
  • F. Hoffmann-La Roche AG
  • Agilent Technologies
  • Illumina Inc.
  • Thermo Fisher Scientific.
  • Macrogen Inc.
Customization ScopeFree report customization with purchase

Next Generation Sequencing Market Segmentation:

  • By Offerings
    • Hardware
    • Software & Services
  • By Type
    • Genome Sequencing
    • Exome Sequencing
    • Targeted Sequencing
  • By Method
    • Sequencing By Synthesis (SBS)
    • Ion Semiconductor Sequencing
    • Nanopore Sequencing
    • Others
  • By Application
    • Oncology
    • Infectious Disease Diagnostics
    • Drug Discovery & Development
    • Others
  • By End-Users
    • Hospitals & Clinics
    • Academic & Research Institutes
    • Pharmaceutical & Biotech Companies
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Indonesia
      • Thailand
      • Taiwan
      • Others

Frequently Asked Questions (FAQs)

The global next generation sequencing (NGS) market is valued at USD 16.696 billion in 2025 and is projected to reach USD 36.778 billion by 2030, growing at a CAGR of 17.11% during the forecast period.

Market growth is fueled by increasing genome mapping programs, rising adoption in oncology research, technological advancements in sequencing platforms, and greater investments in R&D from both government and private sectors.

Key restraints include high equipment and operational costs, limited skilled professionals, and budget constraints in academic and research institutions, especially in developing economies.

Major end-users include pharmaceutical and biotechnology companies, academic and research institutes, and hospitals and clinical laboratories. These sectors use NGS for drug development, genetic diagnostics, and personalized medicine.

North America leads due to advanced healthcare infrastructure, strong funding, and leading biotech firms. Asia-Pacific is emerging rapidly, supported by government-backed genome initiatives and expanding research capacities in China and India.

Table Of Contents

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. NEXT GENERATION SEQUENCING MARKET BY OFFERINGS

5.1. Introduction

5.2. Hardware

5.3. Software & Services

6. NEXT GENERATION SEQUENCING MARKET BY TYPE

6.1. Introduction

6.2. Genome Sequencing

6.3. Exome Sequencing

6.4. Targeted Sequencing

7. NEXT GENERATION SEQUENCING MARKET BY METHOD

7.1. Introduction

7.2. Sequencing By Synthesis (SBS)

7.3. Ion Semiconductor Sequencing

7.4. Nanopore Sequencing

7.5. Others

8. NEXT GENERATION SEQUENCING MARKET BY END-USERS

8.1. Introduction

8.2. Oncology

8.3. Infectious Disease Diagnostics

8.4. Drug Discovery & Development

8.5. Others

9. NEXT GENERATION SEQUENCING MARKET BY END-USERS

9.1. Introduction

9.2. Hospitals & Clincs

9.3. Academic & Research Institutes

9.4. Pharmaceutical & Biotech Companies

9.5. Others

10. NEXT GENERATION SEQUENCING MARKET BY GEOGRAPHY

10.1. Introduction

10.2. North America

10.2.1. USA

10.2.2. Canada

10.2.3. Mexico

10.3. South America

10.3.1. Brazil

10.3.2. Argentina

10.3.3. Others

10.4. Europe

10.4.1. Germany

10.4.2. France

10.4.3. United Kingdom

10.4.4. Spain

10.4.5. Others

10.5. Middle East and Africa

10.5.1. Saudi Arabia

10.5.2. UAE

10.5.3. Israel

10.5.4. Others

10.6. Asia Pacific

10.6.1. China

10.6.2. India

10.6.3. Japan

10.6.4. South Korea

10.6.5. Indonesia

10.6.6. Thailand

10.6.7. Taiwan

10.6.8. Others

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

11.1. Major Players and Strategy Analysis

11.2. Market Share Analysis

11.3. Mergers, Acquisitions, Agreements, and Collaborations

11.4. Competitive Dashboard

12. COMPANY PROFILES

12.1. F. Hoffmann-La Roche AG

12.2. Agilent Technologies

12.3. Illumina, Inc.

12.4. Thermo Fisher Scientific.

12.5. Macrogen, Inc

12.6. BGI Group

12.7. Qiagen

12.8. DNASTAR

12.9. Pacific Biosciences of California, Inc.

12.10. Bio-Rad Laboratories, Inc.

13. APPENDIX

13.1. Currency 

13.2. Assumptions

13.3. Base and Forecast Years Timeline

13.4. Key benefits for the stakeholders

13.5. Research Methodology 

13.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

F. Hoffmann-La Roche AG

Agilent Technologies

Illumina, Inc.

Thermo Fisher Scientific.

Macrogen, Inc

BGI Group

Qiagen

DNASTAR

Pacific Biosciences of California, Inc.

Bio-Rad Laboratories, Inc.

Related Reports